oestrogen – kdc

CLINICAL USE

Second line haemostatic agent for uraemic bleeding

DOSE IN NORMAL RENAL FUNCTION

0.6 mg/kg/day for 5 days

PHARMACOKINETICS

Molecular weight :–

%Protein binding :–

%Excreted unchanged in urine : –

Volume of distribution (L/kg) :–

half-life – normal/ESRD (hrs) :–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Unknown dialysability. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Ciclosporin: concentration of ciclosporin increased

Anticoagulants: antagonism of anticoagulant effect of coumarins and phenindione

Anti-epileptics: accelerate metabolism of oestrogens

ADMINISTRATION

Reconstition

To 50 mL with sodium chloride 0.9%

Route

Rate of Administration

Over a minimum of 30 minutes

Comments

–

OTHER INFORMATION

Duration of effect about 14 days Used in association with desmopressin (DDAVP) in intractable casesOrally

10 to 20 : mg daily for 5–7 days Conjugated oestrogens are a mixture of sodium oestrone sulphate and sodium equilin sulphate and other oestrogenic substances of the type excreted by pregnant maresoestrogen, conjugated (unlicensed product).

Tags: post-by-auto-php